Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Grant revenue	$ 9,737,974	$ 7,144,872
Operating expenses:
Research and development	18,798,343	8,438,499
General and administrative	9,166,762	6,519,268
Total operating expenses	27,965,105	14,957,767
Loss from operations	(18,227,131)	(7,812,895)
Other income:
Other income (expense)	(991)	5,421,592
Interest income	1,937,427	219,430
Total other income, net	1,936,436	5,641,022
Net loss	$ (16,290,695)	$ (2,171,873)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (2.02)	$ (0.82)
Weighted average shares outstanding, basic and diluted (in shares)	8,073,155	2,661,416
Comprehensive loss:
Net unrealized gain on marketable securities	$ 56,197	$ 0
Total comprehensive loss	$ (16,234,498)	$ (2,171,873)